- Corporate Officers - Q
- Quinlan Paul T
Insider Trading History of Quinlan Paul T
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Quinlan Paul T since 2015.
This trader's CIK number is 1333277.
At the time of last reporting, Quinlan Paul T was the General Counsel of Oruka Therapeutics, Inc.. (stock ticker symbol ORKA).
Also see all insider trading activities at Oruka Therapeutics, Inc..
Note that in the past
Quinlan Paul T also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Cymabay Therapeutics, Inc. (CBAY) by Quinlan Paul T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | CBAY | 0 | $0 | 5,000 | $117,899 | 46,824 | $344,691 |
| 2023 | CBAY | 0 | $0 | 88,000 | $1,380,332 | 88,000 | $258,720 |
Yearly summary of insider trading at Oruka Therapeutics, Inc. (ORKA) by Quinlan Paul T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2026 | ORKA | 0 | $0 | 733 | $30,272 | 0 | $0 |
Yearly summary of insider trading at Solazyme Inc (TVIA) by Quinlan Paul T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | TVIA | 0 | $0 | 25,000 | $20,225 | 0 | $0 |
| 2016 | TVIA | 0 | $0 | 20,934 | $48,197 | 0 | $0 |
| 2015 | TVIA | 0 | $0 | 12,811 | $35,820 | 0 | $0 |
Insider trading activities at 3 companies by Quinlan Paul T:
1. Cymabay Therapeutics, Inc. (CBAY)
2. Oruka Therapeutics, Inc. (ORKA)
3. Solazyme Inc (TVIA)
Table 1. Insider trading of Cymabay Therapeutics, Inc. (CBAY) by Quinlan Paul T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-03-13 | CBAY | Option Ex | 41,824 | 7.89 | 329,991 |
| 2024-01-16 | CBAY | Sale | 5,000 | 23.58 | 117,899 |
| 2024-01-16 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-12-15 | CBAY | Sale | 5,000 | 21.98 | 109,905 |
| 2023-12-15 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-11-15 | CBAY | Sale | 5,000 | 17.38 | 86,890 |
| 2023-11-15 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-10-16 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-10-16 | CBAY | Sale | 5,000 | 13.76 | 68,800 |
| 2023-09-15 | CBAY | Option Ex | 53,000 | 2.94 | 155,820 |
| 2023-09-15 | CBAY | Sale | 53,000 | 16.87 | 894,057 |
| 2023-08-15 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-08-15 | CBAY | Sale | 5,000 | 11.91 | 59,550 |
| 2023-07-14 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-07-14 | CBAY | Sale | 5,000 | 11.81 | 59,050 |
| 2023-06-30 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-06-30 | CBAY | Sale | 5,000 | 10.05 | 50,250 |
| 2023-05-15 | CBAY | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-05-15 | CBAY | Sale | 5,000 | 10.37 | 51,830 |
Table 2. Insider trading of Oruka Therapeutics, Inc. (ORKA) by Quinlan Paul T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2026-03-16 | ORKA | Sale | 733 | 41.30 | 30,272 |
Table 3. Insider trading of Solazyme Inc (TVIA) by Quinlan Paul T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-03-09 | TVIA | Sale | 25,000 | .81 | 20,225 |
| 2016-10-14 | TVIA | Sale | 10,000 | 2.55 | 25,530 |
| 2016-09-16 | TVIA | Sale | 3,124 | 2.60 | 8,128 |
| 2016-09-13 | TVIA | Sale | 1,562 | 2.74 | 4,273 |
| 2016-03-10 | SZYM | Sale | 4,686 | 1.64 | 7,666 |
| 2016-03-08 | SZYM | Sale | 1,562 | 1.67 | 2,600 |
| 2015-09-15 | SZYM | Sale | 1,562 | 3.08 | 4,814 |
| 2015-09-17 | SZYM | Sale | 1,562 | 3.14 | 4,910 |
| 2015-03-09 | SZYM | Sale | 9,687 | 2.69 | 26,096 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Quinlan Paul T
(General Counsel of Oruka Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.